JP2024521398A5 - - Google Patents
Info
- Publication number
- JP2024521398A5 JP2024521398A5 JP2023575695A JP2023575695A JP2024521398A5 JP 2024521398 A5 JP2024521398 A5 JP 2024521398A5 JP 2023575695 A JP2023575695 A JP 2023575695A JP 2023575695 A JP2023575695 A JP 2023575695A JP 2024521398 A5 JP2024521398 A5 JP 2024521398A5
- Authority
- JP
- Japan
- Prior art keywords
- gip
- seq
- cex
- a13aib
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21178712.2 | 2021-06-10 | ||
| EP21178712 | 2021-06-10 | ||
| PCT/EP2022/065826 WO2022258805A1 (en) | 2021-06-10 | 2022-06-10 | Treatment of obesity and obesity-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521398A JP2024521398A (ja) | 2024-05-31 |
| JP2024521398A5 true JP2024521398A5 (enExample) | 2025-07-28 |
Family
ID=76502668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575695A Pending JP2024521398A (ja) | 2021-06-10 | 2022-06-10 | 肥満及び肥満関連障害の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277813A1 (enExample) |
| EP (1) | EP4351630A1 (enExample) |
| JP (1) | JP2024521398A (enExample) |
| KR (1) | KR20240021212A (enExample) |
| CN (1) | CN117881415A (enExample) |
| AU (1) | AU2022289247A1 (enExample) |
| BR (1) | BR112023024968A2 (enExample) |
| CA (1) | CA3221661A1 (enExample) |
| IL (1) | IL309128A (enExample) |
| MX (1) | MX2023014740A (enExample) |
| WO (1) | WO2022258805A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| KR20250095833A (ko) * | 2023-12-19 | 2025-06-27 | 한미약품 주식회사 | 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026046202A1 (zh) * | 2024-08-26 | 2026-03-05 | 博瑞生物医药（苏州）股份有限公司 | Glp-1/gip肽或含有其的药物组合物的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070115947A (ko) * | 2005-02-11 | 2007-12-06 | 아밀린 파마슈티칼스, 인크. | 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| SG11202105586YA (en) * | 2018-12-03 | 2021-06-29 | Antag Therapeutics Aps | Modified gip peptide analogues |
| US20250346647A2 (en) * | 2019-12-03 | 2025-11-13 | Antag Therapeutics Aps | Optimized GIP Peptide Analogues |
-
2022
- 2022-06-10 CA CA3221661A patent/CA3221661A1/en active Pending
- 2022-06-10 WO PCT/EP2022/065826 patent/WO2022258805A1/en not_active Ceased
- 2022-06-10 KR KR1020247000556A patent/KR20240021212A/ko active Pending
- 2022-06-10 AU AU2022289247A patent/AU2022289247A1/en active Pending
- 2022-06-10 US US18/565,984 patent/US20240277813A1/en active Pending
- 2022-06-10 IL IL309128A patent/IL309128A/en unknown
- 2022-06-10 CN CN202280040922.8A patent/CN117881415A/zh active Pending
- 2022-06-10 JP JP2023575695A patent/JP2024521398A/ja active Pending
- 2022-06-10 BR BR112023024968A patent/BR112023024968A2/pt unknown
- 2022-06-10 MX MX2023014740A patent/MX2023014740A/es unknown
- 2022-06-10 EP EP22733387.9A patent/EP4351630A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521398A5 (enExample) | ||
| JP7605747B2 (ja) | 修飾されたｇｉｐペプチド類似体 | |
| JP7095027B2 (ja) | 新規のアミリン及びカルシトニン受容体アゴニスト | |
| JP6017754B2 (ja) | グルカゴン／ｇｌｐ−１受容体コアゴニスト | |
| JP2022509568A5 (enExample) | ||
| AU2018338184B2 (en) | Long-acting co-agonists of the glucagon and GLP-1 receptors | |
| EP3212217A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| KR20150131213A (ko) | 인슐린-인크레틴 접합체들 | |
| IL277483B1 (en) | New anti-GLP-1 analogs | |
| TW201010729A (en) | GIP-based mixed agonists for treatment of metabolic disorders and obesity | |
| CN117881415A (zh) | 肥胖症和肥胖症相关障碍的治疗 | |
| JP2023505441A5 (enExample) | ||
| JP2020521784A5 (enExample) | ||
| JP2025172864A5 (enExample) | ||
| RU2024100299A (ru) | Лечение ожирения и связанных с ожирением нарушений | |
| RU2817673C2 (ru) | Модифицированные аналоги GIP пептида | |
| JP2023538871A5 (enExample) |